C OSBORNE to Cell Division
This is a "connection" page, showing publications C OSBORNE has written about Cell Division.
Connection Strength
0.570
-
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.
Score: 0.100
-
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54.
Score: 0.045
-
Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55.
Score: 0.024
-
Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994; 32(1):97-103.
Score: 0.024
-
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec; 47(1-6):83-9.
Score: 0.023
-
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 01; 52(13):3636-41.
Score: 0.021
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95.
Score: 0.020
-
Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991 Jul; 9(7):1283-97.
Score: 0.020
-
Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treat Res. 1991; 53:289-304.
Score: 0.019
-
Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990 Jan; 15(1):3-11.
Score: 0.018
-
Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
Score: 0.018
-
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15; 49(22):6237-41.
Score: 0.018
-
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov; 84(5):1418-23.
Score: 0.018
-
Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov; 3(11):1701-9.
Score: 0.018
-
Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. Horm Res. 1989; 32 Suppl 1:238-41.
Score: 0.017
-
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol. 1988 Nov; 2(11):1064-9.
Score: 0.016
-
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 1988 Jul 15; 48(14):3898-904.
Score: 0.016
-
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-21.
Score: 0.014
-
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb; 45(2):584-90.
Score: 0.013
-
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
Score: 0.011
-
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 2001 Aug 01; 61(15):5771-7.
Score: 0.010
-
Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. J Clin Invest. 1981 Apr; 67(4):943-51.
Score: 0.010
-
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res. 2000 Sep; 6(9):3788-96.
Score: 0.009
-
Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res. 1979 Jul; 39(7 Pt 1):2422-8.
Score: 0.009
-
bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302.
Score: 0.008
-
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
Score: 0.008
-
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A. 1976 Dec; 73(12):4536-40.
Score: 0.007
-
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
Score: 0.007
-
Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res. 1994 Oct 15; 54(20):5357-62.
Score: 0.006
-
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.
Score: 0.006
-
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
Score: 0.006
-
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72.
Score: 0.005
-
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene. 1989 Aug; 4(8):979-84.
Score: 0.004
-
Potential and problems with growth of breast cancer in a human tumor cloning system. Breast Cancer Res Treat. 1981; 1(2):141-8.
Score: 0.002
-
In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med. 1977 Jan 20; 296(3):154-9.
Score: 0.002